Now I have a comprehensive picture. Let me also quickly check the Anthropic partnership news and any last-minute analyst notes to round out the preview.# Cognizant Technology Solutions (CTSH) — Q2 2026 Earnings Preview
Report Date: Wednesday, July 29, 2026 (before market open)
The Setup: A Stock That Has Been Hammered Into the Print
Cognizant walks into this quarter as one of the worst-performing large-cap IT services stocks of 2026. Shares started the year near $81, but a steady deterioration in sentiment around enterprise IT spending — combined with a wave of AI-disruption fears specific to the services industry — has cut the stock roughly in half at its worst point, with an intraday/closing low near $38.73 in late June before a recent bounce to the ~$50 level heading into the print.
Several distinct catalysts drove the decline:
- Sector read-through shock from Accenture (June 18): Cognizant shares plunged 10.49% after industry bellwether Accenture cut its full-year growth outlook and Berenberg downgraded CTSH from Buy to Hold. Accenture's own print showed management flagging that "more of the guided range" was in play for its Q4 given Middle East conflict impacts and large managed-services deals slipping into FY27.
- Nasdaq-100 removal: Nasdaq announced that Cognizant would be removed from the Nasdaq-100 index effective before the market open on June 22, replaced by AI infrastructure names including Rocket Lab and CoreWeave, adding mechanical, index-driven selling pressure on top of the fundamental concerns.
- Infosys guidance cut (July 23, days before CTSH reports): Infosys — a close industry comparable — cut its FY27 revenue growth guidance to 1.5%–3% (from 1.5%–3.5%), citing softer volumes, a client program termination, and, notably, AI-driven pricing deflation and heightened competitive intensity on renewals. This is arguably the most important near-term read-through for CTSH given the timing.
- A cascade of pre-earnings price-target cuts: heading into the print, JPMorgan cut its target to $55 (from $74, Overweight maintained), Baird to $55 (from $72, Neutral), Citigroup to $45 (from $55, Neutral), RBC to $47 (from $88), and Guggenheim to $65 (from $80) while still maintaining a Buy — Guggenheim analyst Jonathan Lee wrote in a July 27 note, cutting his price target to $65 from $80 while maintaining a buy rating, reflecting the Street's expectation that Cognizant will trim its full-year outlook.
- A late curveball: on July 27, Cognizant announced an expanded partnership with Anthropic, becoming a Global Premier Partner in the Claude Partner Network to embed Claude across its industry platforms — helping the stock stage a sharp two-day rally into earnings (roughly +7% each of the last two sessions) even as fundamental caution persists.
What Wall Street Is Modeling
Consensus for Q2 2026 sits at roughly $5.48–5.49 billion in revenue (about 4.4%–4.7% YoY growth) and adjusted EPS of $1.37–$1.38 — the expected profit would mark a slight sequential decline from the $1.40 per share Cognizant delivered in the first quarter, though revenue is projected to edge higher from the prior period's $5.41 billion. Reuters/Investing.com framed the setup bluntly: Wall Street is bracing for what analysts widely expect will be a reduction to the company's full-year outlook as IT spending headwinds intensify.
What Management Guided To Last Quarter
On the Q1 call (April 29), Cognizant delivered a beat-and-raise-ish quarter but flagged a more cautious near-term stance:
- Q1 actuals: Revenue of $5.413B grew 5.8% reported / 3.9% constant currency (CC), adjusted EPS of $1.40 (+13.8% YoY), adjusted operating margin of 15.6% (+10bps YoY). Bookings were a standout — Q1 bookings grew 21% YoY with 7 large deals (≥$100M TCV) including one mega deal (>$500M), pushing TTM bookings to $29.6B (+11% YoY) and book-to-bill to 1.4x.
- Segment mix: Financial Services led with double-digit CC growth (10.2%), driven by banking and insurance; Health Sciences was roughly flat (-0.9% CC) partly due to a ~300bps drag from lower third-party product revenue; Products & Resources grew modestly (+1.1% CC) against trade/macro headwinds; Communications, Media & Technology grew 6.5% CC, helped by ~1,000bps from third-party product sales tied to the integrated-offering strategy.
- Q2 2026 guidance given at the time: revenue of $5.45–$5.52B, or 3.2%–4.7% CC growth, including ~150bps from recently closed acquisitions (3Cloud plus a partial-quarter contribution from the newly announced Astreya deal). Management explicitly called out "a more cautious near-term view of discretionary spending based on recent global events and trends."
- Full-year 2026 guidance (as of Q1): revenue growth of 4.0%–6.5% CC ($22.11–$22.64B), adjusted operating margin of 16.0%–16.2% (raised from a prior 10–30bps expansion target to 20–40bps), and adjusted EPS of $5.63–$5.77 (7%–9% growth). Management's confidence rested on large-deal ramps, two full quarters of Astreya contribution in 2H, and an assumption of some improvement in discretionary spending versus the Q2 assumption.
- Project Leap: a newly launched restructuring/reinvestment program expected to generate $200M–$300M of in-year savings in 2026 (full benefit in 2027), funding AI capability investment and workforce upskilling, with associated charges of $230M–$320M (mostly severance).
- Capital returns: ~$1.6B planned for 2026 ($1B buybacks + ~$600M dividends); Q1 alone saw ~$600M returned and the company ended the quarter with $949M net cash.
Key Things to Watch on Wednesday's Call
- Does full-year guidance get cut? This is the central question. Given Accenture's and Infosys's guidance trims and broadly softer discretionary spending across the industry, the bar is set for Cognizant to either narrow/lower its 4.0%–6.5% CC revenue range or at least walk down the top end. A "reaffirm" would likely be read as a significant positive surprise given how depressed sentiment already is.
- Bookings durability. Q1's 21% bookings growth and 1.4x book-to-bill were the best offsetting data points to macro worries. Investors will want to see whether that momentum continued into Q2 or whether it was a one-quarter phenomenon tied to lumpy large-deal signings.
- Discretionary spending trajectory. Management's original 2H26 assumption baked in improving discretionary spend relative to Q2 — a bet that looks shakier now given Infosys's and Accenture's commentary on elongated decision cycles and cautious clients.
- Pricing/AI deflation dynamics. Peers have flagged intensifying AI-driven productivity pass-throughs and price compression on renewals. Cognizant has argued its ~40% AI-assisted coding and "tokenized rate card" approach let it capture rather than simply give away productivity gains — this quarter's gross margin trend (which fell 80bps YoY in Q1 on integrated-offering and comp costs) will be a real-time test of that thesis.
- Astreya integration and M&A cadence. The Astreya acquisition (AI infrastructure/data-center build-out, per-user outcome-based pricing) was expected to close and start contributing meaningfully in Q3; confirmation of timing and early contribution will matter for the 2H ramp math, as will any update on further M&A given management's stated "healthy and active" pipeline.
- Project Leap execution. Look for updated specifics on realized savings, severance costs booked, and whether margin guidance (16.0%–16.2%) holds or improves.
- Segment-specific color: Financial Services strength, Health Sciences policy/regulatory uncertainty, Products & Resources tariff/trade exposure, and any update on the large customer-specific dynamic weighing on Communications, Media & Technology.
- Capital allocation given the depressed share price. With the stock down roughly 40% from January highs, buyback pace (and whether management leans in opportunistically) will be closely watched — Cognizant still has ~$1.5B of authorization remaining.
- India listing update. Management has said it continues to evaluate a primary offering/secondary listing in India; any incremental detail would be notable.
- AI partnership monetization. The freshly expanded Anthropic/Claude "Global Premier Partner" status (July 27) joins existing ties with Google Gemini, Microsoft/GitHub Copilot, and OpenAI Codex. Investors will want color on whether these translate into bookings/revenue, not just PR.
Bottom Line
CTSH heads into this print as a battered, low-expectations stock — down roughly 40% year-to-date, removed from the Nasdaq-100, and hit by negative sector read-throughs from Accenture and, just days ago, Infosys. Consensus already assumes decelerating sequential EPS and Wall Street broadly expects a guidance trim. That combination means the bar for a "relief rally" may actually be lower than the headline numbers suggest — a reaffirmed full-year outlook, continued strong bookings, and evidence that Project Leap savings and AI-driven pricing are protecting margins could be read favorably even amid mediocre headline growth. Conversely, another cut to full-year revenue or margin guidance, or signs that the AI-driven pricing deflation seen at Infosys is bleeding into Cognizant's book, would likely reinforce the bearish "AI disruption" narrative that has weighed on the stock all year.